GB0526038D0 - Immunogenic composition - Google Patents

Immunogenic composition

Info

Publication number
GB0526038D0
GB0526038D0 GB0526038A GB0526038A GB0526038D0 GB 0526038 D0 GB0526038 D0 GB 0526038D0 GB 0526038 A GB0526038 A GB 0526038A GB 0526038 A GB0526038 A GB 0526038A GB 0526038 D0 GB0526038 D0 GB 0526038D0
Authority
GB
United Kingdom
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0526038A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GB0526038A priority Critical patent/GB0526038D0/en
Publication of GB0526038D0 publication Critical patent/GB0526038D0/en
Priority to EP06830724.8A priority patent/EP1962890B1/en
Priority to US12/097,820 priority patent/US20080311146A1/en
Priority to ES06830724.8T priority patent/ES2558703T3/es
Priority to PCT/EP2006/069944 priority patent/WO2007071692A2/en
Priority to CA 2634898 priority patent/CA2634898A1/en
Priority to JP2008546433A priority patent/JP5780693B2/ja
Priority to JP2013117514A priority patent/JP2013215197A/ja
Priority to US14/598,221 priority patent/US20150125481A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0526038A 2005-12-21 2005-12-21 Immunogenic composition Ceased GB0526038D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GB0526038A GB0526038D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
EP06830724.8A EP1962890B1 (en) 2005-12-21 2006-12-19 Immunogenic composition
US12/097,820 US20080311146A1 (en) 2005-12-21 2006-12-19 Immunogenic Composition
ES06830724.8T ES2558703T3 (es) 2005-12-21 2006-12-19 Composición inmunógena
PCT/EP2006/069944 WO2007071692A2 (en) 2005-12-21 2006-12-19 Immunogenic composition
CA 2634898 CA2634898A1 (en) 2005-12-21 2006-12-19 Immunogenic composition
JP2008546433A JP5780693B2 (ja) 2005-12-21 2006-12-19 免疫原性組成物
JP2013117514A JP2013215197A (ja) 2005-12-21 2013-06-04 免疫原性組成物
US14/598,221 US20150125481A1 (en) 2005-12-21 2015-01-15 Immunogenic Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0526038A GB0526038D0 (en) 2005-12-21 2005-12-21 Immunogenic composition

Publications (1)

Publication Number Publication Date
GB0526038D0 true GB0526038D0 (en) 2006-02-01

Family

ID=35840898

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0526038A Ceased GB0526038D0 (en) 2005-12-21 2005-12-21 Immunogenic composition

Country Status (7)

Country Link
US (2) US20080311146A1 (enExample)
EP (1) EP1962890B1 (enExample)
JP (2) JP5780693B2 (enExample)
CA (1) CA2634898A1 (enExample)
ES (1) ES2558703T3 (enExample)
GB (1) GB0526038D0 (enExample)
WO (1) WO2007071692A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
US7691608B2 (en) 2006-12-06 2010-04-06 Repligen Corporation Nucleic acids encoding recombinant protein A
HRP20160274T1 (hr) 2009-04-03 2016-04-08 University Of Chicago Pripravci i metode vezane za varijante proteina a (spa)
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
JP5793194B2 (ja) * 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
WO2013096948A1 (en) * 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
CN102698260B (zh) * 2012-04-20 2013-09-25 西北农林科技大学 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用
WO2015073801A1 (en) * 2013-11-14 2015-05-21 Duke University Tetanus toxoid and ccl3 improve dc vaccines
CN106163550A (zh) * 2013-12-04 2016-11-23 格林考瓦因有限公司 通过大肠杆菌中合成的糖蛋白疫苗预防金黄色葡萄球菌感染
CN103694322B (zh) * 2013-12-09 2016-08-17 成都欧林生物科技股份有限公司 金黄色葡萄球菌SpA5突变体及其制备方法和应用
MX377794B (es) 2014-03-26 2025-03-10 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
GB201619965D0 (en) * 2016-11-25 2017-01-11 Univ Of Bath The Immunogenic compositions comprising sbi protein and uses thereof
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN115702002A (zh) * 2020-04-23 2023-02-14 朝途生物疗法株式会社 改良肽疫苗
WO2024129976A2 (en) * 2022-12-14 2024-06-20 Scribe Therapeutics Inc. Particle delivery systems

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571514A (en) * 1987-06-01 1996-11-05 Alfa Laval Ab Fibronectin binding protein as well as its preparation
SE9704141D0 (sv) * 1997-11-12 1997-11-12 Sbl Vaccin Ab New protein and nucleotide sequence, encoding said protein
WO2000012132A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
IL141639A (en) 1998-08-31 2005-12-18 Inhibitex Inc Multicomponent vaccines
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US7098383B2 (en) * 2000-12-19 2006-08-29 Sembiosys Genetics Inc. Methods for the production of multimeric immunoglobulins, and related compositions
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
NZ561879A (en) * 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
NZ544542A (en) * 2003-07-24 2009-01-31 Merck & Co Inc Polypeptides for inducing a protective immune response against staphylococcus aureus
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos

Also Published As

Publication number Publication date
ES2558703T3 (es) 2016-02-08
US20080311146A1 (en) 2008-12-18
EP1962890A2 (en) 2008-09-03
JP5780693B2 (ja) 2015-09-16
EP1962890B1 (en) 2015-11-11
US20150125481A1 (en) 2015-05-07
WO2007071692A3 (en) 2007-09-13
WO2007071692A2 (en) 2007-06-28
CA2634898A1 (en) 2007-06-28
JP2009520758A (ja) 2009-05-28
JP2013215197A (ja) 2013-10-24

Similar Documents

Publication Publication Date Title
AP2436A (en) Immunogenic composition
IL181825A0 (en) Immunogenic composition
IL227934A0 (en) Immunogenic preparation
IL186828A0 (en) Vaccine composition
ZA200710909B (en) Immunogenic composition
PL1871347T3 (pl) Kompozycja farmaceutyczna
GB0421079D0 (en) Immunogenic composition
GB0606416D0 (en) Immunogenic composition
ZA200710854B (en) Immunogenic composition
GB0513641D0 (en) Anti-egeing composition
GB0526040D0 (en) Immunogenic composition
GB0515556D0 (en) Immunogenic composition
GB0524204D0 (en) Immunogenic composition
GB0526041D0 (en) Immunogenic composition
GB0503143D0 (en) Immunogenic composition
GB0502569D0 (en) Vaccine composition
GB0421078D0 (en) Immunogenic composition
GB0421081D0 (en) Immunogenic composition
GB0421082D0 (en) Immunogenic composition
GB0606417D0 (en) Immunogenic composition
ZA200702752B (en) Immunogenic compositions
HK1116408A (en) Immunogenic composition
HK1116412A (en) Immunogenic composition
GB0510596D0 (en) Composition
GB0515017D0 (en) Composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)